Altimmune, Inc. is a late clinical-stage biopharmaceutical company developing novel therapies for serious liver diseases. Our lead product candidate, pemvidutide (formerly known as ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis ( MASH ), alcohol use disorder ( AUD ) and alcohol-associ…
The business is unprofitable at the operating level (-230460.98% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 105.0% YoY with margins expanding 285399.0pp.
Negative free cash flow of -$68M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$41K
▲ +105.0% YoY
Net Income (TTM)
-$91M
▲ +7.3% YoY
Op. Margin
-230460.98%
▲ +285399.0pp YoY
ROIC
-31.93%
▲ +12.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$72M
▲ +15.4% YoY
Op. Cash Flow (TTM)
-$72M
▲ +15.4% YoY
Net Debt
-$296M
Net Cash Position
Cash & Equiv.
$332M
5Y CAGR: -65.3%
Continue Research